Académique Documents
Professionnel Documents
Culture Documents
Company Overview
3. What is AFRESA™?
AFRESA™ (insulin human [rDNA origin]) Inhalation Powder is the trade name that
Mannkind has proposed to the FDA for it inhaled insulin product, formerly known as the
Technosphere® Insulin System.
4. Enter into sales and marketing collaborations with other companies, if available on
commercially reasonable terms, or develop these capabilities ourselves.
Diabetes
insulin must be supplied from outside the body in order to sustain life. In type 2 diabetes, the
pancreas continues to produce insulin; however, insulin-dependent cells become resistant
toward the insulin effect. Over time, the pancreas becomes increasingly unable to secrete
adequate amounts of insulin to support metabolism.
16. Are there other problems with currently available insulin therapies?
Because of the limitations mentioned above, patients tend not to comply with the prescribed
treatment regimens and are often undertreated.
More importantly, even when properly administered, subcutaneous injections of insulin do
not replicate the natural time-action profile of insulin. In a person without diabetes, blood
insulin levels rise within several minutes of the entry into the bloodstream of glucose from a
meal. By contrast, injected insulin enters the bloodstream slowly, resulting in peak insulin
levels in about 120 to 180 minutes for regular human insulin or 30-90 minutes for so-called
“rapid-acting” insulin analogs.
The consequence of these slower acting insulins is that patients do not have adequate levels
of insulin present at the initiation of a meal and tend to be over-insulinized between meals.
This lag in insulin delivery results in hyperglycemia early after meal onset, followed by a
tendency for hypoglycemia to develop during the period between meals.
Physicians who treat patients with diabetes are concerned about the risks of hypoglycemia
and, as a result, tend to undertreat the chronic hyperglycemia that is associated with the
disease. However, the resultant extensive hyperglycemia significantly contributes to many of
the long-term cardiovascular and other serious complications of diabetes.
22. Where in the development process is the insulin product? Can you summarize
results?
We are in the process of compiling all of the data from our clinical studies into a new drug
application (or NDA) for AFRESA™. Our goal is to submit the NDA to the United States
Food and Drug Administration by the end of 2008 or shortly thereafter.
23. Why is MannKind persisting with its inhaled insulin product when Pfizer,
NovoNordisk, and Eli Lilly have discontinued their inhalable products?
6
Pfizer’s Exubera was voluntarily withdrawn from the marketplace for commercial reasons.
The Novo and Lilly products were investigational products whose development was
terminated by the companies.
MannKind believes that in order to be successful in today’s health care market, a product
must offer improved efficacy and safety, not just improved convenience. None of the
competitors’ products mentioned offer any advantages over injectable rapid-acting insulin
analogs.
By contrast, in clinical trials to date, AFRESA™ has shown important advantages over rapid-
acting insulin analogs, currently the most effective mealtime therapy. These include:
A significant reduction in post-prandial glucose excursions, approaching the levels seen
in normal people, which are believed to be an important risk factor in the development of
complications from the disease;
The ability to achieve comparable levels of overall glucose control compared with
present "state of the art" treatment, as measured by HbA1c, which is considered the
standard measure of a treatment's effectiveness in diabetes;
A lower risk of hypoglycemia, which is considered to be a major problem for patients
using presently available insulins and many oral treatments, limiting their ability to
optimally treat their disease;
No weight gain and even weight loss in patients treated with AFRESA™, in contrast to
the weight gain that is usually considered a major downside of insulin therapy for many
patients;
No need for complex meal titration, as utilized in our studies to date, significantly
simplifying treatment and reducing the training typically needed for insulin therapy;
No adverse effect on the measures of pulmonary function that have been reported to
occur with other inhaled insulins.
26. Other than AFRESA™, what other products do you have in the pipeline based on
the Technosphere® technology?
Our product MKC253 is a proprietary formulation of human GLP-1 loaded onto
Technosphere® particles. GLP-1 is an incretin, a hormone that stimulates release of insulin
by the pancreas, slows stomach emptying, and reduces food intake. Its effects are less
pronounced in patients with type 2 diabetes. Results from a Phase 1 trial support the
hypothesis that inhalation of MKC253 may be able to simulate the incretin effect that is lost
in patients with type 2 diabetes. Currently we are conducting a second Phase 1 trial to assess
the safety of MKC253.
Our next proposed candidate for development is MKC-180, a novel Technosphere®
formulation of a natural hormone to control satiety for addressing obesity, using pulmonary
delivery. The toxicology studies are underway in order to support a Q2 2009 CTA filing in
Europe. Preclinical animal studies show remarkable reductions in food intake.
27. What products are you working on that are not based on the Technosphere®
technology?
Our cancer program is focused on immunotherapy (inducing the immune system to kill
tumor cells instead of tolerating them) and targeted drug therapies (small molecules that
selectively interfere with a cellular process associated with cancer cells).
The lead compound in our immunotherapy program, MKC1106-PP, is intended for the
treatment of several solid-tumor cancers, including ovarian, colorectal, pancreatic, renal,
breast, non-small cell lung and prostate carcinomas, glioblastoma and melanoma. We are
currently continuing to enroll patients in an open-label Phase 1 clinical trial of the compound.
We have also initiated an open-label Phase 1/2 clinical trial to evaluate a second
immunotherapy compound, MKC1106-MT, in patients with advanced melanoma.
As part of our effort to develop innovative cancer therapies, we have built a drug discovery
group that qualifies targets for high-throughput screening, identifies and optimizes lead
compounds and develops initial preclinical data. We have identified a novel lead class of
compounds that selectively antagonize in vitro an enzyme known as IRE-1. This may lead to
therapies effective for myeloma cells and possibly other malignancies. We have received a
research award from the Multiple Myeloma Research Foundation that will help to support
our optimization and preclinical studies of an IRE-1 antagonist.
Our drug discovery group has identified and optimized a unique class of molecules that
selectively inhibit, in vitro and in vivo, a protein known as ITK. We have received an award
8
from the Leukemia & Lymphoma Society in support of our development of potential ITK
clinical candidates.
CT Operations
30. What investment in CT are you planning going forward? As you expand operations,
will you locate additional facilities in CT?
We believe the Danbury facility will have sufficient space to satisfy potential commercial
demand for the launch of AFRESA™ and, with the expansion completed, the first few years
thereafter for AFRESA™ and other Technosphere®-related products.
31. Was CT’s R&D tax credit exchange a factor in your decision to locate in CT? How
much has the credit been worth to you?
The State of Connecticut provides certain companies with the opportunity to exchange
certain research and development income tax credit carryforwards for cash in exchange for
forgoing the carryforward of the research and development income tax credits. The program
provides for an exchange of research and development income tax credits for cash equal to
65% of the value of corporation tax credit available for exchange. The value of this program
was one of the factors the company considered in deciding to locate operations in Danbury.
Estimated amounts receivable under the program are recorded as a reduction of research and
development expenses. At June 30, 2008, the estimated amount receivable under the program
was $2.25 million.
for employee housing; the existence of a highly educated workforce well trained in
bioscience; and the state’s pleasant environment and high quality of life.
Manufacturing
33. What exactly goes on and will go on at the Danbury manufacturing facilities?
We formulate AFRESA™ from recombinant human insulin and Technosphere® particles,
then fill the AFRESA™ powder into plastic cartridges and commercial operations are
planned to have each cartridge packaged within a foil overwrap.
34. How is your new manufacturing facility flexible, efficient, and cost-effective?
The new facility features state-of-the-art equipment and processes and redundant utilities. It
includes expansion space that will allow us to more than double production capability as
needed. We believe the Danbury facility will have sufficient space to satisfy potential
commercial demand for the launch of AFRESA™ and, with the expansion completed, the
first few years thereafter for AFRESA™ and other Technosphere®-related products.
39. Under what name will you be marketing your lead product?
We have submitted the name AFRESA™ (pronounced uh-FRESS-uh) to the FDA for
review.
###